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ABSTRACT
Homeobox genes are key regulators in normal and malignant hematopoiesis. 
The human Vent-like homeobox gene VENTX, a putative homolog of the Xenopus 
laevis Xvent-2 gene, was shown to be highly expressed in normal myeloid cells and 
in patients with acute myeloid leukemia. We now demonstrate that constitutive 
expression of VENTX suppresses expression of genes responsible for terminal 
erythroid differentiation in normal CD34+ stem and progenitor cells. Transplantation 
of bone marrow progenitor cells retrovirally engineered to express VENTX caused 
massive expansion of primitive erythroid cells and partly acute erythroleukemia in 
transplanted mice. The leukemogenic potential of VENTX was confirmed in the AML1-
ETO transplantation model, as in contrast to AML1-ETO alone co-expression of AML1-
ETO and VENTX induced acute myeloid leukemia, partly expressing erythroid markers, 
in all transplanted mice. VENTX was highly expressed in patients with primary human 
erythroleukemias and knockdown of VENTX in the erythroleukemic HEL cell line 
significantly blocked cell growth. In summary, these data indicate that VENTX is able 
to perturb erythroid differentiation and to contribute to myeloid leukemogenesis when 
co-expressed with appropriate AML oncogenes and point to its potential significance 
as a novel therapeutic target in AML.
INTRODUCTION
It has been shown that early developmental genes 
play a major role in adult hematopoiesis including 
orchestrating self-renewal and differentiation of 
hematopoietic stem and progenitor cells. This is 
exemplified by the family of homeobox genes, known 
to be key regulators in embryogenesis, but also during 
normal postnatal hematopoiesis [1]. Furthermore, it 
was shown that the role of homeobox genes extends 
beyond normal hematopoiesis, being critically involved 
in leukemogenesis. This role is well established for 
clustered HOX genes such as HOXA9, but also for non-
clustered homeobox genes such as MEIS1, which is one 
of the most potent co-factors for HOX driven leukemias, 
or the Parahox gene CDX2 [2–4]. We recently described 
                  Research Paper
Oncotarget86890www.impactjournals.com/oncotarget
the human Vent-like homeobox gene VENTX, a putative 
homolog of the Xenopus laevis Xvent-2 gene, as a novel 
regulatory hematopoietic gene, which in contrast to 
leukemogenic HOX genes such as HOXA9 and HOXA10 
is highly expressed in normal myeloid cells, but not in 
early CD34+ stem and progenitor cells. Constitutive 
expression of VENTX in normal CD34+ human 
progenitor cells impaired lymphoid engraftment and 
fostered generation of myeloid cells, but failed to induce 
leukemia in vivo. This was in contrast to our observation 
that VENTX was highly expressed in human AML, in 
particular in patients with the translocation t(8;21) which 
is associated with the most frequent fusion gene AML1-
ETO (AE) [5]. We now provide evidence that VENTX 
suppresses expression of erythroid master regulators, 
expands primitive erythroid cells and contributes to 
leukemogenesis in transplanted mice.
RESULTS
VENTX impairs expression of genes involved in 
erythroid differentiation and is highly expressed 
in patients with acute erythroid leukemia and 
polycythemia vera
Based on our previous findings that overexpression 
of VENTX is able to perturb normal hematopoietic 
differentiation, we first aimed at characterizing changes in 
the molecular profile induced by VENTX overexpression. 
For this VENTX was retrovirally expressed in normal 
human CD34+ cord blood (CB) cells for 48h before 
performing RNA-sequencing (RNA-Seq) (n=3). 278 genes 
were differentially expressed between VENTX and the 
empty vector control (Supplementary Table S1, Figure 1A). 
Pathway analyses showed changes in the expression of genes 
belonging to the categories JAK-STAT signaling pathway, 
Hematopoietic cell lineage, Cytokine-cytokine receptor 
interaction and Hemoglobin's Chaperone (Supplementary 
Figure S1A-S1C, Supplementary Table S2). Strikingly, 
overexpression of VENTX significantly downregulated 
genes involved in erythropoiesis, among them several 
genes known as master regulators of erythropoiesis: thus, 
genes such as GATA1 (2.7-fold, p<0.0001), GATA2 (2.3-
fold, p<0.0001), LDB1 (1.7-fold, p=0.001), KLF1 (5.0-
fold, p<0.0001), GFI1B (2.5-fold, p<0.0001), LMO2 
(1.7-fold, p<0.001) and TAL1 (2.3-fold, p<0.0001) 
were downregulated in CD34+ CB cells constitutively 
expressing VENTX. In parallel genes involved in heme and 
hemoglobin synthesis were significantly downregulated 
such as HBA1 (4.1-fold, p=0.0001), HBB (4.1-fold, 
p<0.0001), HBD (7-fold, p<0.0001), HBG1 (2.8-fold, 
p<0.001), HBG2 (5.9-fold, p<0.0001) and EPOR (2.6-
fold, p<0.001) (Figure 1B, Supplementary Table S1). 
Gene set enrichment analysis focusing on genes known to 
be involved in erythroid differentiation showed a highly 
significant negative enrichment in VENTX overexpressing 
cells compared to the empty vector control (Figure 1C). 
Of note, around every 10th gene of our data set overlapped 
with proteins expressed during erythroid differentiation 
as recently shown by quantitative mass spectrometry to 
determine the absolute proteome composition of human 
erythroid progenitors throughout the differentiation process 
(Supplementary Table S3) [6].
As we saw suppression of genes driving erythroid 
maturation, we tested first the expression of VENTX 
in the human primitive erythroblastic cell line HEL 
compared to other myeloblastic cell lines and normal 
erythroid cells: of note, highest expression was seen in 
HEL with a significant and 2.8-fold higher expression than 
in HL60 cells (p<0.001). Furthermore, HEL expressed 
VENTX 2.2-fold and 2.3-fold higher than normal highly 
purified Glycophorin A positive peripheral blood or 
BM, respectively (p≤0.001) (Figure 2A). In line with 
data from primary AML samples [5], there was high 
expression in the t(8;21) positive cell lines Kasumi-1 and 
SKNO-1 (Figure 2A). Analyses were extended to primary 
erythroleukemias (AML M6) and polycythemia vera 
patient samples, documenting high expression of VENTX 
in clear contrast to PML-RARα positive AML, which did 
not show any detectable expression of VENTX as well as 
in contrast to CD34+ progenitor cells from normal bone 
marrow (Figure 2B, Table 1). To test whether expression 
levels of VENTX correlate with promoter methylation, 
DNA methylation of a total of 59 AML patients (54 
normal karyotype (CN) AML samples, five samples with 
t(8;21)) was quantified by MassARRAY technology in 
comparison to normal CD34-enriched cord blood and PB 
of healthy individuals. A wide range of mean amplicon 
DNA methylation levels (4% to 86%) was observed in 
the set of 54 AML samples with normal karyotype for 
amplicon 1 versus low DNA methylation levels (10% to 
21%) in hematopoietic progenitor cells from cord blood 
and in sorted subfractions from peripheral blood (10% to 
19%). The t(8;21) positive AML samples did not cluster 
separately at the amplicon 1 region but exhibited overall 
low DNA methylation levels (7% to 20%) (Supplementary 
Figure S2A-S2C).
Expression levels of VENTX were compared to 
DNA methylation in 8 NPM1 mutated patient samples 
(Table 1) as well as in sorted CD3+, CD14+, CD15+, 
CD19+ and GlyA+ subfractions from PB and CD34+CD38-, 
CD34+CD38+, CD34-CD38+ subpopulations from CB, 
respectively. However, there was no significant correlation 
between the VENTX expression and the level of DNA 
methylation of amplicon 1 and amplicon 2 in all cell 
populations tested (data not shown).
To evaluate, whether leukemic cells depend on 
VENTX expression, the impact of shRNA mediated 
depletion of VENTX on growth of HEL cells was tested: 
knockdown of VENTX expression by 98.85% and 99.43% 
for shVENTX_73 and shVENTX_77, respectively, 
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Figure 1: A. Heatmap of differentially expressed genes as determined by RNA-seq between CD34+ CB cells overexpressing VENTX 
compared to the empty vector control (n=3). B. Differentially expressed genes transcription factors, which are known to play a role in 
erythroid development. ****: p<0.0001, ***: p≤0.0001, **: p≤0.001. C. Gene set enrichment analysis of genes involved in erythropoietic 
differentiation.
Figure 2: A. Quantitative expression of VENTX in different AML cell lines compared to BM CD34+/BMNCs/BM GlyA+/PB GlyA+. All 
expression analyses were performed by TaqMan® qRT-PCR with (+)RT and (-)RT reaction samples. Fold expression values were obtained 
by normalizing the expression of the gene of interest (VENTX) to the endogenous human β-actin (β-Act). Bars are showing the average 
fold expression ± SEM. *: p≤0.05, **: p≤0.001, ***: p≤0.0001, ****: p<0.0001. B. Mean Quantitative expression of VENTX AML M6 and 
PML-RARα positive AML samples compared to Glycophorin A from BM/PB and CD34+ bone marrow cells. All expression analyses were 
performed by TaqMan® qRT-PCR with (+)RT and (-)RT reaction samples. Log2 fold expression values were obtained by normalization of the 
expression of the gene of interest (VENTX) to the endogenous human β-actin. Bars are showing the log2 fold expression ± SEM. **: p≤0.001 
and ****: p<0.0001. ○ indicates no detectable expression for 5 individual samples of PML-RARα positive AML cases (for up to 37 cycles).
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Table 1: Patients’ characteristics
Patient no. Diagnosis Gender Age Karyotype Other relevant markers
1 AML M6a M 77
46,XY,del(5)(q22q34),+8,dic(15;17)
(p11;p11),der(20;21)(p10;q10),+der(20;21) 
(p10;q10) [16]
DNMT3A, TP53
2 AML M6a M 48 46,XY,del(11)(p11p14) [11]46,XY [9] none
3 AML M6 M 74
48,XY,+8,+8 [4]
48,XY,der(6)t(6;6)(p25;q12),+8,+8 [15]
46,XY [1]
DNMT3A, RUNX1, TP53
4 AML M6 F 81
46,XX,t(4;10)(q13;p12) [3]
45,XX,t(4;10)(q13;p12),del(5)(q31q35),-7 [3]
46,XX [4]
TET2, 
TP53
5 AML M6 M 71 47,XY,+8 [10]46,XY [10] ASXL1
6 AML M6 F 38 46,XX ASXL1, FLT3-ITD, NPM1 mut
7 AML M6: tAML F 59
92-96,XXX,-X,2xadd(4)(q35),
-7,+?12,+22,+1-3mar TET2
8 AML M6: AML M 56
46,XY,del(20)(q11) [5]
46,XY [12]
ASXL1, 
IDH2, 
MLL-PTD
9 AML M6: sAML F 57 48,XX,+8,+19 TET2
10 AML M6 F 42 46,XX,inv(9)(p11q13)c
IDH1, 
NPM1 mut, 
WT1
11 AML M 75 45,X,-Y [16]46,XY [4] FLT3-ITD, NPM1 mut
12 AML F 45 46,XX [20] NPM1 mut
13 AML M 74 46,XY [20] FLT3-TKD, NPM1 mut
14 AML M 46 46,XY [20] FLT3-ITD, NPM1 mut
15 AML F 27 46,XX [21] NPM1 mut
16 AML F 46 46,XX,del(9)(q13q22) [10]46,XX [10] NPM1 mut
17 AML F 40 46,XX [21] FLT3-TKD, NPM1 mut
18 AML F 49 46,XX [23] FLT3-ITD, NPM1 mut
19 PV F 70 46,XX [18] JAK2
20 PV M 81 46,XY [20] DNMT3A,JAK2
21 PV M 60 46,XY [20] JAK2
22 PV F 65 46,XX [21] ASXL1,JAK2
23 PV M 76 46,XY [20] JAK2
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resulted in a mean reduction of cell growth of 81% 
(76%-84%) and 95% (91%-98%) after 6 days in liquid 
culture (n=3) (Figure 3). We extended these analyses 
to other leukemic cell lines such as K562 and OCI-
AML3 cell lines. Similar findings were detected, when 
VENTX was knocked down in these cell lines with a 
significant reduction in cell proliferation, colony growth in 
methylcellulose, as well as survival and engraftment levels 
in NSG mice (for OCI-AML3) (data not shown). The 
efficiency of the shRNA mediated knockdown of VENTX 
on the protein level was measured after overexpression of 
VENTX in HEL cells by intracellular staining. As shown 
in Supplementary Figure S3 we could demonstrate, that 
knockdown of VENTX resulted in a decrease of VENTX 
protein as determined by a weaker fluorescent signal.
We performed an Annexin V staining and a BrdU 
assay to evaluate, whether cell cycle arrest, apoptosis or 
senescence might contribute to the oncogenic cooperativity 
in the AML1-ETO mouse model. Knockdown of VENTX 
lead to a 2.4-fold increase of the proportion of non-cycling 
cells as compared to the scrambled control arm. Using the 
Annexin V staining, we did not detect an increase of early 
or late apoptotic cells when VENTX was knocked down 
(data not shown).
VENTX expands the primitive erythroid 
compartment and causes acute leukemia in 
transplanted mice
To extend analyses on the functional relevance 
of VENTX overexpression, the homeobox gene was 
constitutively expressed in mouse BM progenitor cells 
and transplanted into lethally irradiated mice. Of note, 
all transplanted mice (n=18) showed an accumulation 
of blasts in the BM and infiltration in the spleen with 
undifferentiated and erythroid blasts (median 47%, range 
29%-85%). (Supplementary Table S4). 3 of 18 mice 
developed overt clinical disease and died after 153, 189 
and 249 days, respectively (Figure 4A) with an infiltration 
of 29%, 85% and 60% blasts in the bone marrow, 
respectively. The blasts were mostly undifferentiated 
with a substantial proportion displaying an erythroblast 
phenotype (24%, 95% and 55%, respectively) (Figure 
4B and Supplementary Table S4). Leukemias were 
readily transplantable in 13 of 19 mice tested with disease 
development after short latency (median 14 days, range 
11-67 days) (Figure 4A) and high erythroblast counts in 
the bone marrow, spleen and peripheral blood in secondary 
mice (Supplementary Table S4, Figure 4B). These blasts 
lacked expression of myeloid markers and were highly 
positive for Ter119 (median 86.8%, range 76.9 – 95.2%) 
and partly CD71 (median 45%, range 1 – 79.3%) (Figure 
4C and Supplementary Table S5). Histological analyses 
in VENTX diseased mice showed the presence of 
erythroblasts with the diagnosis of an erythroleukemia 
according to the Bethesda criteria for non-lymphoid 
hematopoietic neoplasms (Figure 4D) [7].
To confirm the leukemogenic potential of VENTX 
we co-expressed the homeobox gene with the fusion gene 
AML1-ETO in the bone marrow transplantation assay. The 
rationale for this was that we have seen high expression of 
VENTX in patients with AML1-ETO positive leukemia 
Figure 3: Cell proliferation in liquid expansion cultures from HEL cells after shRNA mediated knockdown of VENTX (shVENTX_73, 
shVENTX_77) compared to the scrambled control. Knockdown efficiency was 99% for both shRNA constructs (n=3).
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among others before [5]. Furthermore, it was previously 
shown, that AE is only able to induce leukemia with 
a leukemogenic partner in transplanted mice [8–10]. 
All mice (n=20) transplanted with AE plus VENTX 
developed leukemia after a median of 337.5 days (range 
19-403 days) post-transplantation (Figure 4A). Leukemias 
were characterized by high blast counts of mean 68.5% 
in the bone marrow (range 38 - 100%) (Supplementary 
Table S4, Figure 5A) and expression of progenitor cell 
and myeloid markers: Sca-1 (median 20.5%, range 11.8-
32.4%) and c-kit (median 8.5%, range 2.9 – 78.5%), Gr-1 
(median 34.7%, range 3.0 – 52.3%) and Mac-1 (median 
33.2%, range 0-67.1%) (Figure 5B, Supplementary Table 
S5). Surprisingly, myeloid blasts expressed CD71 in the 
bone marrow, which we did not see in our AML1-ETO 
bone marrow transplantation model overexpressing FLT3-
LM (Figure 5B) [8]. Strikingly, secondary diseased mice 
displayed partly large nodules consisting of erythroblasts 
extending to diffuse erythroblastic infiltration in the spleen 
in other mice. The white pulp was almost eradicated with 
few residual B220 and CD3 positive cells (Figure 5C). 
Leukemias were readily transplantable in secondary 
(n=14) and tertiary recipient mice (n=9) (median 129 days, 
range 13 to 343 days for secondary and median 14 days, 
range 13 to 18 days for tertiary mice) (Figure 4A). BM of 
diseased mice displayed an infiltration of the bone marrow 
with CD71 (median 46.7%, range 22.5 - 72%) and CD36 
(median 82%, range 60.2 – 90.7%) expressing cells. To 
exclude retroviral insertional mutagenesis in VENTX and 
AE/VENTX induced leukemias, integration sites were 
sequenced: there was one, but not recurrent site enlisted 
in the retroviral tagged cancer genes database (RTCGD) 
(Supplementary Table S6). Leukemic cells originating 
from diseased AE/VENTX mice showed 250-fold (± 30) 
and 713-fold (± 90) increased colony formation and re-
plating capacity ex vivo, respectively (p<0.05), compared 
to BM cells isolated from mice transplanted with cells 
expressing AE alone (Figure 6). Cytospins of generated 
colonies showed blast morphology with >50% of blast 
cells/blasts. Cells from a secondary AE/VENTX mouse 
showed permanent but growth factor (rmIL3, rmSCF, 
rmIL6) dependent cell growth, blast morphology, and high 
Figure 4: A. Kaplan-Meier survival curves of mice transplanted with 5-FU stimulated transduced BM cells expressing AML1-
ETO+VENTX [AE/VENTX 1°] (n=20), VENTX [VENTX 1°] (n=18), empty vector control (n=18) and AML1-ETO [AE 1°] (n=15). 
Secondary and tertiary transplantations are shown for leukemic mice: AE/VENTX 2° (n=14), AE/VENTX 3° (n=9), VENTX 2° (n=19), 
VENTX 3° (n=4). AE/V 1° - V 1° V = VENTX: **, p= 0.0011; AE/V 1° - empty vector control 1°: ****, p<0.0001; AE/V 1° - AE1°: 
****, p <0.0001; V 1° - empty vector control 1°: n.s. (n.s. = not significant); V 1° - AE1°: ns; AE/V 2° - V 2°: ns; AE/V 3° - V 3°: ns. B. 
Representative cytomorphological analyses of bone marrow of a diseased VENTX transplanted 1° mouse compared to an empty vector 
control mouse. C. Representative flow cytometric analysis of a primary VENTX recipient mouse (left side) and a secondary VENTX 
recipient mouse (right side) D. Histological analysis of primary (left side) and secondary (right side) VENTX recipient mice.
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expression of CD71 (87.4%), whereas Ter119 as well as 
Gr-1, Mac-1, Sca-1 and c-kit were virtually not expressed, 
corresponding to the immunophenotype of erythroid 
precursors [11] (data not shown). This cell population 
maintained its leukemogenicity in vivo and rapidly 
induced leukemia in transplanted mice (n=3) within 14 
days (13 - 14 days). Engrafted cells expressed Ter119 and 
maintained the erythroblastic phenotype (Supplementary 
Figure S4A-S4B). When placed in methylcellulose assay 
cells from this cell line generated undifferentiated serially 
replatable colonies, which expressed CD71 (85.6%) and 
were negative for Sca-1, c-kit, Ter119, Gr-1, Mac-1 (data 
not shown).
DISCUSSION
This report documents for the first time that aberrant 
expression of the homeobox gene VENTX contributes to 
the development of acute myeloid leukemia and by this 
extends the list of non-clustered homeobox genes with 
leukemogenic potential. We reported previously that 
VENTX is highly expressed in various subtypes of AML, 
but failed to prove on a functional level that the gene is 
directly involved in myeloid leukemogenesis, possibly 
also because of the limitations of xenograft models to 
mirror the effect of oncogenes to a full extent [5]. In our 
current bone marrow transplantation model, aberrant 
expression of VENTX was able to induce acute leukemia 
in a part of transplanted mice after long latency, indicating 
that VENTX needs collaborative partners to exert its full 
leukemogenic potential. One of the candidates for such 
an oncogenic partner is the most frequent fusion gene in 
human AML, AML1-ETO, as we had seen high expression 
of VENTX in patients with AML1-ETO positive AML 
[5]. AML1-ETO is able to increase self-renewal of 
hematopoietic stem- and progenitor cells, but is not overt 
leukemogenic as shown in several independent mouse 
and human experimental models [8–10, 12–15]. VENTX 
induced AML in all transplanted mice in collaboration 
with AML1-ETO, characterizing VENTX as a novel 
collaborative partner of AML1-ETO. With this, VENTX 
is among the first homeobox genes shown to cooperate 
with AML1-ETO, as we could just recently demonstrate 
Figure 5: A. Representative cytomorphological analysis of bone marrow cytospins of diseased mice as indicated (AE/VENTX 1° and 
2°) compared to a representative non-leukemogenic AE 1° mouse. B. Representative flow cytometric analysis of a primary AE/VENTX 
recipient mouse (left side) and a secondary AE/VENTX recipient mouse (right side) C. Histological analysis of two secondary transplanted 
AE/VENTX mice, showing erythroblasts in the spleen of the diseased animals.
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that the TALE homeobox gene MEIS2 collaborates with 
the fusion in inducing AML [16]. It also demonstrates that 
the transcription factor AML1-ETO can collaborate with 
its own class as VENTX is a bona fide transcription factor. 
Following the classical two hit model proposed previously 
[17, 18], leukemic transformation depends on two factors, 
one conferring self-renewal and the other one impairing 
differentiation of hematopoietic progenitor cells. AML1-
ETO has a well-established function as a factor increasing 
self-renewal [19]. Although the two-hit model is surely 
an oversimplification of complex AML biology, it would 
require that VENTX impairs differentiation. Indeed, the 
most surprising observation was that VENTX induced 
expansion of primitive erythroid cells up to erythroblastic 
leukemia on its own and induced AML with partly 
erythroid features together with AML1-ETO. This went 
along with suppression of several erythroid master 
regulators of erythroid differentiation, resulting in a highly 
significant negative enrichment score for expression of 
these factors in VENTX overexpressing cord blood cells. 
We had not seen this erythroblastic phenotype in our own 
AML1-ETO - FLT3-LM model or from the perspective 
of homeobox genes in our AML models depending on 
homeobox gene expression [4, 8, 20, 21]. However, it 
has been described previously, that AML1-ETO positive 
leukemias show an impairment in erythroid differentiation 
[22–25]. This might indicate, that VENTX impairs in 
particular differentiation along the erythroid line in 
hematopoietic progenitor cells enforced to self-renew by 
the AML1-ETO fusion. In line with this overexpression 
of VENTX in CD34+ cord blood cells resulted in a nearly 
complete block of erythroid differentiation with an 81% 
reduction of the number of BFU-E as previously reported 
by us [5]. Our data demonstrate that aberrant expression 
of VENTX has leukemogenic potential. Importantly, Gao 
et al recently described that VENTX can act as a potential 
tumor suppressor gene in solid cancer cell lines originating 
from lung and colon cancer [26]. Furthermore, the same 
group previously demonstrated that VENTX is able to 
impair cell growth in chronic lymphocytic leukemia [27]. 
All these data indicate that the function of VENTX largely 
depends on the cellular context and that VENTX can act 
Figure 6: Ex vivo colony forming cell assay (CFC1) and re-plating assays (CFC2, CFC3) of leukemic cells isolated from mice transplanted 
initially with 5-FU BM cells transduced with the different constructs as indicated. Results are means ± SEM. The number of CFC refers to 
1000 input cells in the primary CFC assay. For 2° and 3° CFC assay also the CFC numbers are indicated per initially plated 1000 cells for 
the primary CFC (*: p≤0.05).
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as tumor suppressor and as oncogene. This has to be taken 
into account, if therapeutic approaches are considered 
which are targeting VENTX dependent functions or 
VENTX itself.
Taken together, our data extend the number 
of homeobox genes critically involved in myeloid 
leukemogenesis, but also underline that the role of this 
gene family in tumorigenesis can critically depend on the 
cancer subtype.
MATERIALS AND METHODS
Human samples and cell lines
Mononuclear cells isolated from diagnostic bone 
marrow (BM) or peripheral blood (PB) from 28 adult 
patients were analyzed for their VENTX expression: 
n=10 for AML M6, n=5 for polycythaemia vera (PV) 
and n=5 for PML-RARα, n=8 for NPM1 mutated AML. 
CD34+ bone marrow mononuclear cells (BMNCs) and 
CD34+ cord blood (CB) cells (both from Lonza, Cologne, 
Germany) (n=5 and n=3) as well as sorted subfractions 
from peripheral blood and bone marrow from healthy 
individuals were taken as controls [5]. Cytomorphological, 
cytogenetic and molecular analyses were performed in all 
cases as described. Cases were classified according to the 
French-American-British criteria and the World Health 
Organization classification (Table 1) [28, 29]. The study 
was approved by the ethics committees of all participating 
institutions, and informed consent was obtained from 
all patients before they entered the study in accordance 
with the Declaration of Helsinki (http://www.wma.net/
en/30publications/10policies/b3/index.html).
All cell lines used were obtained from DSMZ, 
Braunschweig, Germany. Original stocks were frozen 
down and all experiments were performed with 
aliquots from the original stock with less than 6 months 
propagation in vitro. DSMZ guarantees originality of 
cell lines by comprehensive molecular testing e.g. by 
polymerase chain reaction (PCR) amplification of eight 
highly polymorphic microsatellite STR loci, using the 
uniqueness of DNA profiles in an STR database. For 
RNA-Seq experiments, human cord blood cells were 
retrovirally transduced with VENTX or an empty vector 
control as described previously [5].
Quantification of VENTX expression
Total RNA was isolated using the Direct-zol™ 
Kit (Zymo Research, Freiburg, Germany) and TRIzol®-
Reagent. To avoid genomic DNA contamination all RNA 
samples were treated with DNaseI enzyme according 
to the manufacturer’s instructions (ThermoFisher, 
Darmstadt, Germany). cDNA was prepared using random 
hexamer primers (Primescript RT-PCR kit; TAKARA 
Clontech, Saint-Germain-en-Laye, France) according to 
the manufacturer’s instructions. For endogenous control, 
the human β-actin gene (β-Act) was used. Reactions were 
run in duplicates or triplicates with 50 ng cDNA input 
material per detection well in a total reaction volume of 
20 μl on an ABI PRISM 7900 HT Fast Real-Time PCR 
Sequence Detection System (ThermoFisher). Expression 
of VENTX was assayed by TaqMan® quantitative real-
time polymerase chain reaction (qRT-PCR) in the HEL 
erythroid leukemia as well as Kasumi-1, SKNO-1, 
HL60, NB4 and OCI-AML3 cell lines and in patient 
samples with AML M6 as well as polycythaemia vera 
and compared to patient samples with PML-RARα and 
sorted subpopulations of peripheral blood and BM from 
healthy donors. For VENTX the human TaqMan® probe 
Hs00797729_s1 was used (ThermoFisher). Primer and 
probes for analyzing the expression of VENTX were 
selected specifically for that gene, in order to prevent 
amplification of known VENTX pseudogenes. The relative 
expression of each gene was determined by calculating 
fold change (2-ΔCt) to the housekeeping gene (β-Act).
LM-PCR
For the linker-mediated PCR (LM-PCR), integrated 
Yellow and Green Fluorescent Protein (YFP and GFP) 
and flanking genomic sequences were amplified and 
then isolated using a modification of the bubble LM-
PCR strategy [30]. Aliquots of the cell lysates from 
leukemic mouse bone marrow (BM) and spleen (SP) 
were digested with PstI (New England Biolabs Inc., 
Frankfurt a.M, Germany), and the fragments were ligated 
overnight at 16°C to a double-stranded bubble linker 
(5′CTCTCCCTTCTCGAATCGTAACCGTTCGTACG
AGAATCGCTGTCCTCTCCTCCTGCA3′ and 5′GG
AAGGAGAGGACGCTGTCTGTCGAAGGTAAGG
AACGGACGAGAGAAGGGAGAG3′). Next, a first 
PCR (PCR-A) was performed on 10μl (one-tenth) of the 
ligation product using a linker specific Vectorette primer 
(5′CGAATCGTAACCGTTCGTACGAGAATCGCT3′) 
(ThermoFisher) and a GFP/YFP-specific primer (GFP/
YFP-A: 5′ACTTCAAGATCCGCCACAAC3′) under the 
following conditions: 1 cycle of 94°C for 2 minutes, 30 
cycles of 94°C for 30 seconds and 65°C for 1 minute, 
and 1 cycle of 72°C for 2 minutes. The bubble linker 
contains a 30-nucleotide non-homologous sequence in the 
middle region that prevents binding of the linker primer 
in the absence of minus strand generated by the LTR-
specific primer. A 1μl-aliquot of the PCR-A reaction (one-
fifteenth) was then used as a template for a second, nested 
PCR (PCR-B) using an internal GFP/YFP-specific primer 
(GFP/YFP-B: 5′ACATGGTCCTGCTGGAGTTC3′) and 
the same linker-specific Vectorette primer as was used in 
PCR-A, with the following conditions: 1 cycle of 94°C 
for 2 minutes, 35 cycles of 94°C for 60 seconds and 72°C 
for 1 minute, and 1 cycle of 72°C for 2 minutes. 100μl 
of the final PCR-B product were electrophoresed using a 
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2% agarose tris-acetate EDTA gel. Individual bands were 
excised and purified using the illustra GFX PCR DNA and 
Gel Band Purification Kit (GE Healthcare Life Sciences, 
Freiburg, Germany). The eluted samples were sequenced 
with the Vectorette primer by LGC genomics (Berlin, 
Germany). The sequences were then aligned using BLAST 
(www.ncbi.nlm.nih.gov/BLAST/) to identify the genomic 
location of the flanking sequences. Identified genomic loci 
were screened using the retroviral tagged cancer genes 
database (RTCGD).
Retroviruses and plasmids
MSCV based retroviral vectors were used for 
overexpression of AML1-ETO (AE) and VENTX. The 
VENTX cDNA was provided by Paul Moretti (Institute 
of Medical and Veterinary Science, Adelaide, Australia) 
and subcloned into the retroviral pMSCV-IRES-YFP 
vector, as previously described [31]. The AE construct 
was subcloned into the GFP vector. As control, an empty 
vector (MSCV vector carrying only the IRES and GFP or 
YFP-cassette) was used (empty vector control).
Transduction and BM transplantation
Stable packaging cell lines were generated for 
the different constructs and used for BM experiments 
as reported previously [21]. 5-FU BM was transduced 
with empty vector (control), VENTX, AE alone or with 
AE plus VENTX (AE/VENTX) in four, six, five and 
four independent experiments, respectively. Successfully 
transduced BM cells were transplanted unsorted into 
lethally irradiated (12 Gy) recipient mice. Transduction 
efficiency was on average 12.8% (2.2%-19.4%) or 0.7% 
(0.1%-1.2%) for VENTX alone and AE/VENTX double-
transduced cells, respectively, 6.8-40.1% for the empty 
vector control and 26.1% (4.5%-36.9%) for AE. As donor 
mice > 12-week-old (C57Bl/6Ly-Pep3b x C3H/HeJ) F1 
(PepC3) mice, as recipients > 12-week-old (C57Bl/6J x 
C3H/HeJ) F1 (B6C3) mice were used. The number of 
transplanted cells ranged from 4.5x105 to 3.7x106 cells 
per mouse for VENTX and from 4x104 to 2x106 cells 
per mouse for AE/VENTX (for AE 2.1x105 – 2x106 cells 
per mouse, for the empty vector control (ctrl.) 1.8x106 – 
3.3x106 cells per mouse). For secondary transplantation 
between 8.7x104 (plus once with 2.1x105 helper cells) to 
1x106 unsorted cells from primary diseased mice were 
transplanted per mouse, for tertiary transplantation the 
number of transplanted cells per mouse ranged from 0.5 to 
0.6x106 unsorted BM cells from primary diseased animals.
CD34 positive human cord blood cells were 
retrovirally transduced with VENTX and the empty 
vector control as described previously [5]. After 48 hours 
successfully transduced cells were highly purified and 
subjected to RNASeq analysis.
shRNA mediated VENTX knockdown
For stable shRNA mediated knockdown 
of endogenous VENTX genes, pLKO.1 based 
lentiviral vectors were used: pLKO.1 empty vector 
(SHC001), pLKO.1 scrambled (SHC002), pLKO.1-
shVENTX_77 (TRCN0000015977, GenBank 
accession no. NM_014468.3), pLKO-1-shVENTX_73 
(TRCN0000015973) (all obtained from Sigma-Aldrich, 
Munich, Germany). shVENTX_77 and shVENTX_73 
oligonucleotides were cloned into the pGreenPuro vector 
(System Biosciences, California, USA). shRNA mediated 
knockdown in human cell lines was achieved following 
the experimental procedure as described previously [5].
For lentiviral transduction, Lenti-X™ 293T 
(Clontecth, #632180) cells were transiently transfected 
with CaCl2. Lenti-X™ 293T cells were cultured in a 10 
cm dish to a confluency of 70%. Virus containing medium 
(VCM) was collected and filtered through a 0.45 μm filter. 
VCM was concentrated with an ultracentrifuge 1:100.
Intracellular staining
For intracellular staining HEL cells were transduced 
in order to overexpress an HA-tagged construct of 
VENTX. Afterwards an shRNA mediated knockdown of 
VENTX was performed. 75,000 of these cells were spun 
with 450 rpm for 10 min onto microscope slides. Then, 
cells were fixed with 4% PFA for 10 min at RT, followed 
by a washing step in PBS. In order to permeabilize the 
cells, cells were treated with 0.1% Triton-X 100 for 
5 min at RT. Afterwards cells were treated with pre-
cooled pure Ethanol (cooled to -20°C) for 15 min at 
-20°C, before they were washed with PBS and blocked 
with 10% BSA for 1hr at RT. After blocking, cells were 
washed in PBS and incubated with the primary antibody 
anti-HA, rabbit (Abcam, 1:300 dilution) for 2 hrs at RT. 
Then, cells were washed with PBS and stained with the 
fluorescent secondary antibody goat-anti-rabbit-Alexa 
Fluor 594(1:1000 dilution) for 1 hr at RT in the dark. 
Then, cells were washed with PBS and nuclei were stained 
with DAPI (1:1000) for 3 min at RT. Cells were again 
washed with PBS and mounted with antifade fluorescent 
mounting medium and covered with a cover slip. Slides 
were analyzed with a fluorescent microscope.
Colony forming cell (CFC) assay and cytospin
Hematopoietic colony forming cell (CFC) assays 
were performed using methylcellulose supplemented 
with murine cytokines (MethoCult GF M3434, Stem 
Cell Technologies, Cologne, Germany) as previously 
described [21]. 7 days after setting up the CFC, number 
and morphology of the colonies were assessed. For testing 
the clonogenic potential of leukemic BM from diseased 
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mice 1-3x104 cells per dish were plated for primary 
CFC and 500 to 5x103 cells for re-plating assays. For 
cytomorphological analyses by cytospin 0.1x106 cells 
were spun onto a microscope slide by a centrifugation 
step for 5 min at 350 rpm. The number of CFC for the first 
and second re-plating experiments was calculated for 1000 
cells initially plated cells (CFC1), thereby accounting not 
only for the number of CFC per plated cell but also for the 
number of cells generated per CFC.
Flow cytometric analysis
Cells were stained according to standard protocols. 
Cells were resuspended in PBS and treated with 1% 
ammonium chloride solution (10 min on ice). 1x105 
cells/FACS tube were resuspended in 100 μl of PBS 
and incubated on ice for 10 min with a purified rat anti-
mouse CD16/32 antibody (BioLegend, Fell, Germany) to 
block non-specific antibody binding. After blocking, cells 
were stained for 20 min on ice. The following antibodies 
were used for flow cytometric analyses of murine bone 
marrow cells and permanently growing cells of a diseased 
mouse: Ter119 and CD36 labeled with APC (both 
BioLegend), B220 and Ter119 labeled with eFluor450 
(both eBioscience, Frankfurt, Germany), Mac-1 labeled 
with qDot605 (BioLegend). Antibodies labeled with 
Alexa Fluor 700 were used against the epitope of c-kit 
(eBioscience), Gr-1 was labeled with APC-Cy7 (both 
BioLegend), Sca-1 with PE-Cy5.5 (Caltag) and CD71 with 
PE-Cy7 (Becton Dickinson and BioLegend, respectively). 
Cells were analyzed using a FACS FORTESSA LSR II 
(Becton Dickinson, Heidelberg, Germany).
BrdU staining
BrdU staining was performed according to the 
manufacturer’s instructions (BD Pharmingen BrdU Flow 
Kit, BrdU-APC). Briefly, 100,000 cells (HEL-SCR, HEL-
shVENTX_73, HEL-shVENTX_77) were starved in 
RPMI supplemented with 1% FBS and 1% Pen/Strep for 
16 hrs. Afterwards FBS was added in order to obtain a 
final concentration of 10% FBS and cells were incubated 
in that medium for another 24 hrs. BrdU treatment was 
performed for 30 min at 37°C.
Annexin V staining
Annexin V apoptosis assay was performed 
according to the manufacturer’s instructions (BD, APC 
Annexin V apoptosis Detection Kit).
Bisulfite conversion and quantitative DNA 
methylation analysis (MassARRAY)
Bisulfite conversion and quantitative DNA 
methylation analysis (MassARRAY) was performed 
as described preciously [32]. Briefly, genomic DNA 
(gDNA) of sorted subpopulations from peripheral 
blood and cord blood from healthy donors was isolated 
according to the manufacturer’s instructions using the 
column based DNeasy Blood & Tissue purification Kit 
(Quiagen, Hilden, Germany). Afterwards, gDNA samples 
were bisulfite-modified using the EZ DNA methylation 
kit (Zymo Research, Freiburg, Germany). The specific 
primer sequences used for PCR amplification are available 
upon request. The MassARRAY EpiTYPER Assay was 
performed at Sequenom Inc. (Hamburg, Germany) as 
described previously [33]. Amplicon 1 was located on 
chromosome 10:133237067-133237565, Amplicon 2 on 
chromosome 10: 133237570-133238054. The coordinates 
were based on genome version GRCh38/hg38 Dec 2013. 
After amplification, PCR products were transcribed in 
vitro before being cleaved by RNase A and subjected to 
matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS). Methylation 
standards were used as controls and for normalizing data, 
while standards had 0%, 20%, 40%, 60%, 80%, and 100% 
of methylated genomic DNA.
RNA-Seq methods
For cord blood experiments (VENTX, CD34+) 
sequencing libraries were prepared using Illumina 
TruSeq™ RNA Kit (Illumina, Inc.). All samples were run 
on the Illumina HiSeq2000 platform. The raw paired-end 
reads were adapter trimmed and quality filtered (phred 
score of > 20) using the cutadapt wrapper trim galore 
[34]. Filtered sequences were aligned to the human hg19 
RefSeq using tophat and differential expression analyses 
were performed using Cufflinks with downstream analysis 
in R and Bioconductor [35–37].
Gene set enrichment analysis
Gene Set Enrichment Analysis (GSEA) was 
performed using the GSEA tool from broad MIT [38], 
using the set of significantly differentially expressed 
genes from the RNA-Seq analysis generated from CB cells 
transduced with either VENTX or the empty vector control 
(n=3, respectively). GSEA focused on genes known to be 
involved in erythropoietic differentiation.
Histopathology
For histological analyses, sections of selected organs 
were prepared and stained using standard protocols as 
previously described [4, 8].
Statistical analyses
Data were evaluated using the t test for independent 
samples. Differences with p values less than 0.05 were 
considered to be statistically significant (* p≤0.05; 
** p≤0.001; *** p≤0.0001; **** p<0.0001). Values 
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mentioned are Mean ± SEM. PRISM GraphPad PRISM® 
software, Prism 6 (Version 06.01) for Windows, Microsoft 
Excel 2010 was used to determine the correlation 
coefficients, Version 6.01 (La Jolla, California, USA) 
was used for the analysis and figures and FACSDiva 8.0 
(Becton Dickinson) to analyze the FACS plots.
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